IDEMIA Partners With RHB Bank to Launch the First Recycled Debit Card in Asia Pacific
16.6.2020 06:00:00 EEST | Business Wire | Press release
IDEMIA and RHB Bank champion sustainability with a new line of eco-friendly RHB debit card, in partnership with WWF-Malaysia and Visa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005593/en/
(Photo: Business Wire)
IDEMIA, the global leader in Augmented Identity, today announced the launch of the first eco-friendly recycled PVC payment card in Asia Pacific with RHB Bank, headquartered in Malaysia. Designed for its banking customers, RHB Bank created the RHB Visa WWF Debit Card-i cards in partnership with IDEMIA, WWF-Malaysia, and Visa, as part of the bank’s efforts to strengthen its commitment in sustainable practices and to raise public awareness in the conservation and environmental sustainability of the marine ecosystem.
As part of its environmental strategy, IDEMIA confirms its commitment to move away from today’s linear take-make-waste model and fundamentally rethink the way we design, use and reuse plastics. The partnership between RHB Bank and IDEMIA demonstrates the shared desire to be pioneers in this initiative.
Plastic recycling is beneficial in many ways (including C0² emission reduction) and one of the most significant impacts is industrial waste reduction versus first-use materials. These recycled PVC payment cards save a total mass of 3.18g industrial waste per finished card, which can amount in thousands of tons of material saved if the industry moves in this direction.
These RHB Visa WWF Debit Card-i will be available to all existing RHB customers and new customers in Malaysia in July 2020. The cards contain state-of-the-art technology for seamless payment convenience, have passed all durability testing and are ISO-certified and EMV compliant.
“Part of innovation is being aware of the impact that our development has on society and the world we live in. Essentially, it is about finding new solutions that help us harmonise efficiency and sustainability,” said Vincent Mouret, Senior Vice-President of Financial Institutions Asia Pacific at IDEMIA. “IDEMIA is proud to be part of the solution in creating less plastic waste and reducing land and water pollution while optimizing our carbon footprint. Every single contribution we can make towards a greener world matters.”
“Most discarded plastics end up in the ocean to the detriment of marine life. Our new recycled plastic card is our way of contributing directly to the conservation of ocean life through partnering with IDEMIA and global affiliated NGOs such as WWF-Malaysia.” said Dato’ Adissadikin Ali, Managing Director, RHB Islamic Bank Berhad.
RHB Banking Group, headquartered in Malaysia, previously partnered with IDEMIA for a major project in the region. In July 2019, the two companies launched Southeast Asia’s first MOTION CODE™ credit card, a high-tech payment card with a dynamic security code – CVV2 – that changes automatically regularly, reducing the risk of fraud.
-END-
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005593/en/
Contact information
Press contacts:
PR firm: Havas Paris
Hanna Sebbah
+33 (6) 63 73 30 30.
idemia@havas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
